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Abstract
OBJECTIVE—To evaluate the relationships between excessive gestational weight gain, neonatal 
adiposity, and adverse obstetric outcomes in women with mild gestational diabetes mellitus 
(GDM).
METHODS—This is a secondary analysis of a multicenter randomized clinical trial of women 
with mild GDM. Based on self-reported prepregnancy body weight, gestational weight gain was 
categorized as excessive if it was greater than 2009 Institute of Medicine guidelines. Maternal 
outcomes and neonatal anthropomorphic characteristics were compared between women with 
excessive weight gain and those without excessive weight gain. Multiple linear and logistic 
regression analyses were performed to adjust for confounding factors.
RESULTS—We studied 841 women who participated in the main trial and had prepregnancy 
BMI and delivery information available (n= 431 treatment group, n= 410 no treatment). After 
Corresponding author: Sean C. Blackwell, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
Texas Health Science Center at Houston, 6431 Fannin, Suite 3.286, Houston, Texas 77030, Sean.Blackwell@uth.tmc.edu, Office: 
713-500-6415, FAX: 713-500-0799.
*For a list of the other members of the Eunice Kennedy Shriver NICHD MFMU Network, see Appendix 1 online at http://
links.lww.com/xxx.
Presented in part at the 30th annual meeting of the Society for Maternal-Fetal Medicine, Chicago, Illinois, February 1-6, 2010.
HHS Public Access
Author manuscript
Obstet Gynecol. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Obstet Gynecol. 2016 December ; 128(6): 1325–1332. doi:10.1097/AOG.0000000000001773.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
adjustment for factors including treatment and prepregnancy BMI, excessive weight gain remained 
associated with LGA (aOR 2.94, 95% CI 1.81-4.93), BW > 4000 grams (aOR 2.56, 95% CI 
1.54-4.40), preeclampsia (aOR 2.96, 95% CI 1.35-7.03) and cesarean delivery for labor arrest 
(aOR 2.37, 95% CI 1.30-4.44). In addition, excessive weight gain was independently associated 
with increased total neonatal fat (p < 0.001) and birth weight (p < 0.001).
CONCLUSION—In women with both treated and untreated mild GDM, excessive gestational 
weight gain was independently associated with both greater birth weight and adiposity.
Introduction
Excessive gestational weight gain is defined as weight gain during pregnancy beyond the 
recommended thresholds from the 2009 Institute of Medicine (IOM) guidelines.1,2 It is 
estimated that approximately 40-50% of all pregnant women have excessive gestational 
weight gain.3 There is ample literature that describes an increased risk for both maternal and 
newborn adverse outcomes in women with excessive weight gain.4-6 This includes the risk 
for excessive fetal growth (e.g. large for gestational age [LGA] and macrosomia) which can 
then predispose the offspring to obesity later in life. Several studies have linked maternal 
weight gain during pregnancy and to child obesity and adiposity.7-9
Women with gestational diabetes mellitus (GDM) have an increased risk for LGA and 
macrosomic birth weights (compared to women without GDM).10,11 Although there are 
robust data regarding the interaction of weight gain and maternal obesity in non-diabetic 
women, there is limited information regarding the impact of excessive weight gain on 
pregnancy outcomes in women with mild GDM (who make up a large portion of all women 
with GDM). This data is important to clinicians to know whether IOM guidelines for weight 
gain in pregnancy apply to women with mild GDM.
Because of the potential short and long-term impact of excessive fetal growth in utero, we 
performed this analysis to evaluate the relationship between excessive gestational weight 
gain and measures of newborn growth and adiposity in women with both treated and 
untreated mild GDM. Our secondary goal was to evaluate the relationship between excessive 
gestational weight gain and various perinatal outcomes.
Materials & Methods
This is a secondary analysis of a randomized clinical trial (RCT) for women with mild GDM 
(enrollment October 2002-November 2007).12 The study was approved by the human 
subjects committee at each participating center; all women enrolled provided written 
informed consent. This secondary analysis was approved by the Committee for Protection of 
Human Subjects at the University of Texas Health Sciences Center at Houston. Women 
across all clinical sites were included in the analysis. Women eligible for the RCT had a 
singleton pregnancy, gestational age between 24 weeks 0 days and 30 weeks 6 days 
gestation, and met criteria for mild GDM. Mild GDM was defined as a fasting glucose less 
than 95 mg/dl with two or three timed glucose measurements exceeding the pre-defined 
thresholds (one hour ≥180 mg/dl, two hour ≥155 mg/dl, and three hour ≥140 mg/dl). 
Treatment included either formal nutritional counseling plus diet therapy (along with insulin 
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therapy if required) versus no treatment. Women were excluded from the trial if they had 
pre-existing diabetes, abnormal glucose screening prior to 24 weeks, GDM in a prior 
pregnancy, history of stillbirth, known fetal anomaly, current or planned corticosteroid use, 
asthma, chronic hypertension, chronic medical disease, and maternal or fetal conditions 
likely to require imminent or preterm delivery.
Women in the treatment arm received formal nutritional counseling and performed daily 
self-blood glucose monitoring (fasting and 2-hour postprandial measurements). Insulin was 
prescribed if the majority of values between study visits were elevated (fasting glucose ≥95 
mg/dl, two-hour post-meal glucose ≥120 mg/dl). Clinical management including the timing 
and mode of delivery were at the discretion of the patient's attending physician. Those in the 
no treatment arm were managed in routine fashion, as caregivers, patients, and research staff 
were unaware of whether or not the subject met criteria for mild GDM or had normal OGTT 
testing.
Self-reported pre-pregnancy BMI (kg/m2) and gestational weight gain (pounds) were 
recorded for each study participant. Women were categorized as underweight (BMI < 18.5 
kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), and obese 
(BMI ≥ 30 kg/m2).13 Gestational weight gain was defined as excessive if it exceeded the 
total weight gain recommendations from the IOM (underweight women > 40 lbs., normal 
weight > 35 lbs., overweight > 25 lbs., and obese > 20 lbs.).2 Demographic and clinical 
characteristics, perinatal outcomes, and neonatal anthropomorphic measures were compared 
between women who had “excessive weight gain” versus those with “normal weight gain.” 
Given the rarity of weight gain being less than IOM recommendations, we collapsed those 
with less than targeted range and those with normal weight gain into same group.
Pre-specified study definitions and outcome measures were used for the study. Preeclampsia 
was defined as elevation in blood pressure (systolic ≥ 140 mm Hg or diastolic value ≥ 90 
mm Hg on two occasions at least 4 hours apart or one elevated blood pressure value 
subsequently treated with antihypertensive medication) and proteinuria (urine collection ≥ 
300 mg/24 hours or ≥ 2+ on dipstick in the absence of a 24-hour collection). Elevated blood 
pressure with either elevated liver enzymes (SGOT ≥ 100 U/L) or thrombocytopenia 
(platelet count <100,000/mm3) also signified preeclampsia. Shoulder dystocia was defined 
clinically and required documentation of maneuvers specifically employed to disimpact the 
fetal shoulders. Large for gestational age (birth weight > 90th percentile) and small for 
gestational age (birth weight<10th percentile) were based on prior published normative 
values.14 Cesarean delivery for labor arrest was defined as cesarean done for any of the 
following indications: cephalopelvic disproportion, failure to progress, failed induction, 
failed forceps/vacuum or arrest of descent. Using a standardized approach, flank skin fold 
measurement, length, head circumference and upper mid-arm circumference were performed 
(within 72 hours if possible) and neonatal fat mass was calculated.15 Neonatal fat mass was 
reported as both total fat mass in grams as well as percentage of total weight (fat mass 
[grams] / total weight [grams]).
Statistical analysis was performed with SAS software. Chi-square or Fisher's exact test (in 
the case of infrequent outcomes) was used to compare categorical variables, Student's T test 
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or Wilcoxon Rank Sum test (in the case on non-normal distribution) was used to compare 
continuous variables. Presence of an interaction between treatment group and excessive 
weight gain with the outcomes, or between treatment group and pre-pregnancy BMI 
category [≥ 30 kg/ m2 vs. <30 kg/ m2] with the outcomes, was tested using the Breslow-Day 
test for homogeneity of the odds ratios for categorical variables and analysis of variance for 
continuous variables. Multivariable linear regression was performed to evaluate continuous 
dependent variables (neonatal birth weight, fat mass, and percent fat mass) adjusting for 
independent variables (maternal race/ethnicity [Hispanic vs. not Hispanic], maternal age, 
gestational age at enrollment, parity [nulliparous vs. multiparous], gestational age at 
delivery, treatment group, pre-pregnancy BMI category [≥ 30 kg/ m2 vs. <30 kg/ m2], and 
gestational weight gain [excessive vs. normal]. Multivariable logistic regression was 
performed with dependent variables, BW > 4000 grams, preeclampsia, cesarean delivery, 
and chorioamnionitis including the same independent variables, and for LGA and SGA 
including the same independent variables except for gestational age at delivery. Separate 
regression models by treatment group were generated for any outcome where there was a 
significant interaction between excessive weight gain and treatment group or between 
excessive weight gain and pre-pregnancy BMI category. A nominal 2-sided P value of < 0.05 
was considered to indicate statistical significance, and no adjustments were made for 
multiple comparisons.
Results
There were 958 enrolled in the RCT and delivery data was available for 932 women. Of 
these, 841 women had data pre-pregnancy BMI information and were included in this 
secondary analysis (n= 431 treatment group, n= 410 no treatment). Treatment was associated 
with a lower rate of excessive weight gain in the cohort (40.4% vs. 54.2%; RR=0.75, 95% 
CI 0.65 - 0.86; p<0.001). The demographic and clinical characteristics of the study 
population are described in Table I. Selected maternal and neonatal outcomes based on the 
presence or absence of excessive weight gain are summarized in Table II. Women with 
excessive weight gain who did not receive treatment for GDM had newborns with greater 
birth weight, higher frequency of LGA, BW > 4000 grams, and greater newborn fat mass. In 
addition, they were more likely to be diagnosed with preeclampsia.
Women with excessive weight gain in the treatment arm were more likely to have birth 
weight > 4000 grams, and have greater birth weight and fat mass. They were also more 
likely to undergo cesarean delivery.
Listed in Table III are the perinatal outcomes for study participants based on presence or 
absence of pre-pregnancy maternal obesity. In those who underwent GDM treatment there 
were no differences in obstetrical outcomes or indices of neonatal anthropomorphics based 
on maternal obesity. However, in those without treatment, offspring of obese mothers had 
greater neonatal fat mass (p=0.019) and fat mass percentage (p= 0.005). Table IV describes 
outcomes only for obese women and compares perinatal outcomes based on normal or 
excessive weight gain by treatment group. In untreated obese women, excessive weight gain 
was associated with greater neonatal fat mass, neonatal fat mass percentage, and birth 
weight. However, in those who were treated there were no differences in neonatal fat mass 
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or birth weight. The only difference in outcomes for those with treatment was that those with 
excessive weight gain had greater risk for cesarean delivery for labor arrest (p = 0.007).
Multiple logistic and linear regression analyses were performed to adjust for confounding 
factors including GDM treatment and pre-pregnancy BMI (obese versus non-obese) in order 
to evaluate the effects of weight gainon perinatal outcomes and neonatal anthropometric 
characteristics. Separate models by GDM treatment group were generated for the outcome 
SGA, since there was a significant interaction between treatment group and weight gain with 
SGA (p=0.015), and for the outcome fat mass percent, since there was a significant 
interaction between treatment group and pre-pregnancy BMI category with fat mass percent 
(p=0.04). Table V describes the associations between excessive weight gain and selected 
neonatal and maternal outcomes: After adjustment for confounding factors, excessive weight 
gain was significantly associated with the following outcomes: LGA (aOR 2.94, 95% CI 
1.81-4.93), BW > 4000 grams (aOR 2.56, 95% CI 1.54-4.40), preeclampsia (aOR 2.96, 95% 
CI 1.35-7.03) and cesarean delivery for labor arrest (aOR 2.37, 95% CI 1.30-4.44). In these 
same models, once we adjusted for excessive weight gain, pre-pregnancy obesity was not 
significantly associated with an increased risk for adverse outcomes. Multiple linear 
regression analyses were performed to assess the associations between excessive weight gain 
and maternal obesity on neonatal anthropomorphic characteristics. After adjustment for key 
variables, excessive weight gain was independently associated with increased total neonatal 
fat, neonatal fat mass percentage (in those without treatment), and birth weight. Pre-
pregnancy maternal obesity was also associated with increased total neonatal fat, neonatal 
fat mass percentage (in those without treatment), but not overall newborn birth weight (Table 
VI).
Discussion
We found in our secondary analysis that 1) GDM treatment decreases maternal weight gain, 
2) the rate of excessive weight gain remains relatively high at 40.1% despite GDM 
treatment, 3) after adjustments for important clinical factors including GDM treatment and 
maternal obesity, if excessive weight gain developed there was increased neonatal fat mass, 
risk for LGA, and overall increased birth weight, 4) excessive weight gain was associated 
with increased risk for cesarean delivery for labor arrest regardless of GDM treatment and 5) 
after adjustment of important clinical factors including excessive weight gain, maternal 
obesity was not associated with adverse perinatal outcomes but was associated with 
abnormal fetal growth patterns. Moreover, the key finding was that development of excessive 
weight gain was associated with increased risk of abnormal fetal growth independent of 
maternal BMI and GDM treatment, thus emphasizing the clinical relevance of this 
potentially modifiable factor.
Epidemiologic data links excessive weight gain to excessive fetal growth (e.g. LGA and 
macrosomia) as well as childhood and later life obesity in offspring. 6-8,16 In non-diabetic 
women several observational studies have demonstrated an association between excessive 
weight gain and short and long-term measures of excessive offspring growth.17-21 Few 
studies have evaluated these relationships in women with gestational and pre-gestational 
diabetes. In the DEPOSIT study (Diabetes Endocrine Pregnancy Outcome Study in 
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Toronto), Ray and colleagues prospectively studied 428 women with gestational and 196 
women with pre-gestational diabetes over a 5-year period.22 They found that weight gain 
and pre-pregnancy BMI were independent risk factors for adverse neonatal outcomes. Cheng 
et al. evaluated data from 31,074 women with treated GDM who participated in the Sweet 
Success California Diabetes and Pregnancy Program from 2001-2004.23 Women who had 
weight gain above IOM guidelines had higher odds of having LGA newborns (adjusted OR 
1.72, 95% CI 1.53-1.93). Egan and colleagues published data from their cohort 
(ATLANTIC-DIP) in Ireland, which included 543 women with GDM.24 Of these women 
57% had excessive weight gain and after adjustment for confounding factors, in 5 kg interval 
weight gain increments weight gain was associated with increased risk for LGA (aOR 1.3, 
95%CI 1.1–1.6).
A major strength of our study is the evaluation of neonatal fat mass and not just the measure 
of birth weight. The clinical significance and prediction of fetal adiposity for development of 
childhood obesity is greater than birthweight alone; neonatal fat mass is strongly associated 
with development of obesity and metabolic syndrome.25 Additional strengths include use of 
standardized definitions for clinical and outcome variables as well as linear and logistic 
regression analyses to adjust for confounding factors. One limitation of the analysis is the 
fact that measurement of weight gain was in part based on self-reported pre-pregnancy 
weight, since women were not enrolled into the parent trial until the late second trimester. 
Some studies have shown good correlation with maternal recall of prior pregnancy events 
and characteristics (up to 30 years prior) while others have shown lower reliability of 
maternal recall of pre pregnancy weight and weight gain from prior pregnancies.26,27 
Finally, although our findings have generalizability with respect to maternal race/ethnicity 
and maternal size, our findings are limited to women with treated and untreated mild GDM, 
and not all women with GDM or pre-gestational DM.
In summary, excessive weight gain remains frequent in women with mild GDM despite 
treatment and the effects of excessive weight gain on newborn size and anthropometrics are 
independent of maternal BMI. Future clinical trials are warranted to determine whether 
additional interventions specifically designed to limit excessive weight gain in mild GDM 
are beneficial to women and their offspring.
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Table I
Selected demographic and clinical characteristics
Characteristics No Treatment Group Treatment Group
Normal Weight 
Gain N=188
Excessive weight 
gain N=222
P Normal Weight 
Gain N=257
Excessive weight 
gain N=174
P
Maternal age (yrs) 29.8 ± 5.5 28.5 ± 5.4 0.02 29.5 ± 5.7 28.8 ± 5.8 0.21
Race 0.08 0.07
African American 21 (11.2) 30 (13.5) 22 (8.6) 29 (16.7)
Caucasian 58 (30.9) 56 (25.2) 76 (29.6) 44 (25.3)
Hispanic 90 (47.9) 125 (56.3) 143 (55.6) 93 (53.4)
Other 19 (10.1) 11 (5.0) 16 (6.2) 8 (4.6)
Primiparous (%) 66 (35.1) 79 (35.6) 0.92 65 (25.3) 64 (36.8) 0.01
Pre-pregnancy BMI (kg/m2)* 24.7 [22.3-28.8] 26.0 [23.4-28.7] 0.05 25.3 [22.1-28.7] 26.5 [23.7-29.4] 0.02
Pre-pregnancy BMI category*** 0.001 0.03
Underweight 6 (3.2) 4 (1.8) 6 (2.3) 4 (2.3)
Normal 97 (51.6) 80 (36.0) 118 (45.9) 58 (33.3)
Overweight 45 (23.9) 85 (38.3) 84 (32.7) 71 (40.8)
Obese 40 (21.3) 53 (23.9) 49 (19.1) 41 (22.6)
Smoking 12 (6.4) 16 (7.2) 0.74 17 (6.6) 19 (10.9) 0.11
GA at randomization (wks) 29.1 ± 1.5 28.9 ± 1.4 0.22 28.8 ± 1.5 28.9 ± 1.6 0.62
Need for Insulin therapy 0 2 (0.9) 0.50** 14 (5.5) 21 (12.1) 0.01
Data expressed as n (%), mean ± standard deviation, or median [interquartile range]
*
P-value determined by the Wilcoxon rank sum test
**
P-value determined by Fisher's exact test
***
Pre-pregnancy birthweight category: Underweight (< 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obese (≥ 
30.0 kg/m2)
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Table II
Selected perinatal outcomes for study participants based on presence or absence of excessive weight gain by 
treatment group.
Outcome No Treatment Group Treatment Group
Normal Weight 
Gain N=188
Excessive weight 
gain N=222
P Normal Weight 
Gain N=257
Excessive weight 
gain N=174
P
LGA 13 (6.9) 46 (20.8) <0.001 12 (4.7) 16 (9.2) 0.06
BW > 4000 g 15 (8.0) 43 (19.5) <0.001 9 (3.5) 14 (8.1) 0.04
SGA 20 (10.6) 8 (3.6) 0.005 17 (6.6) 14 (8.1) 0.57
Preeclampsia 6 (3.2) 18 (8.1) 0.03 3 (1.2) 7 (4.0) 0.10
Chorioamnionitis 6 (3.2) 14 (6.3) 0.15 10 (3.9) 9 (5.2) 0.52
CD (all) 57 (30.3) 76 (34.2) 0.40 57 (22.2) 59 (33.9) 0.007
CD labor arrest (n=369) 9 (5.5) 21 (11.2) 0.05 9 (4.0) 17 (11.6) 0.005
Neonatal fat mass (gm) 408.3 ± 220.0 495.7 ± 219.1 <0.001 406.8 ± 158.6 448.3 ± 192.9 0.03
Neonatal Fat mass (%) 11.7 ± 5.5 13.4 ± 5.2 0.003 12.1 ± 3.8 12.8 ± 4.8 0.11
Birth weight (gm) 3253.6 ± 626.6 3518.2 ± 551.1 <0.001 3259.9 ± 424.4 3401.1 ± 479.2 0.001
Data expressed as n (%) or mean ± standard deviation
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Table III
Selected perinatal outcomes for study participants based on presence or absence of maternal obesity by 
treatment group.
Outcome No Treatment Group* Treatment Group
Pre-pregnancy BMI 
< 30 N=316
Pre-pregnancy BMI 
≥ 30 N=93
P Pre-pregnancy BMI 
< 30 N=341
Pre-pregnancy BMI 
≥ 30 N=90
P
LGA 43 (13.6) 16 (17.2) 0.39 20 (5.9) 8 (8.9) 0.30
BW > 4000 g 45 (14.2) 13 (14.0) 0.95 16 (4.7) 7 (7.8) 0.29
SGA 24 (7.6) 4 (4.3) 0.27 24 (7.0) 7 (7.8) 0.81
Preeclampsia 16 (5.1) 8 (8.6) 0.20 8 (2.4) 2 (2.2) 1.00
Chorioamnionitis 18 (5.7) 2 (2.2) 0.27 15 (4.4) 4 (4.4) 1.00
CD (all) 96 (30.3) 37 (39.8) 0.09 88 (25.8) 28 (31.1) 0.31
CD labor arrest (n=352) 22 (7.9) 8 (10.7) 0.45 20 (6.7) 6 (8.3) 0.63
Neonatal fat mass (gm) 440.1 ± 215.6 509.0 ± 241.8 0.019 421.3 ± 177.0 434.2 ± 164.9 0.56
Neonatal Fat mass (%) 12.2 ± 5.3 14.1 ± 5.6 0.005 12.3 ± 4.5 12.4 ± 3.3 0.82
Birth weight (gm) 3389.8 ± 590.8 3419.7 ± 637.1 0.67 3308.3 ± 437.8 3349.6 ± 504.2 0.44
Data expressed as n (%) or mean ± standard deviation
*
Birth weight data was missing for one patient
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Table IV
Selected perinatal outcomes for obese women (BMI ≥ 30 kg/m2) based on presence or absence of excessive 
weight gain by treatment group.
Outcome No Treatment Group Treatment Group
Normal Weight 
Gain N=40
Excessive weight 
gain N=53
P Normal Weight Gain 
N=49
Excessive weight 
gain N=41
P
LGA 3 (7.5) 13 (24.5) 0.03 4 (8.2) 4 (9.8) 1.00
BW > 4000 g 3 (7.5) 10 (18.9) 0.12 4 (8.2) 3 (7.3) 1.00
SGA 4 (10.0) 0 (0.0) 0.03 3 (6.1) 4 (9.8) 0.70
Preeclampsia 2 (5.0) 6 (11.3) 0.46 0 2 (4.9) 0.20
Chorioamnionitis 0 (0.0) 2 (3.8) 0.50 1 (2.0) 3 (7.3) 0.33
CD (all) 19 (47.5) 18 (34.0) 0.19 11 (22.5) 17 (41.5) 0.05
CD labor arrest (n=369) 2 (6.7) 6 (13.3) 0.46 0 6 (18.2) 0.007
Neonatal fat mass (gm) 432.6 ± 221.0 564.1 ± 243.3 0.012 425. 4 ± 139.5 444.4 ± 191.9 0.61
Neonatal Fat mass (%) 12.4 ± 5.3 15.3 ± 5.6 0.02 12.5 ± 2.6 12.4 ± 4.0 0.98
Birth weight (gm) 3197.6 ± 752.1 3587. 2 ± 476.9 0.006 3300.2 ± 460.5 3408.7 ± 551.9 0.31
Data expressed as n (%) or mean ± standard deviation
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Table V
Logistic regression analysis results for association of excessive weight gain and of pre-pregnancy obesity with 
selected perinatal outcomes.
Outcome Odds Ratio (95% CI) for Excessive weight 
gain Adjusted/Unadjusted
P-value Odds Ratio (95% CI) for Pre-pregnancy 
Obesity Adjusted/Unadjusted
P-value
LGA 2.94 (1.81-4.93)
3.13 (1.92-5.09)
<0.001
<0.001
1.26 (0.73-2.12)
1.42 (0.86, 2.35)
0.39
0.17
BW > 4000 g 2.56 (1.54-4.40)
2.96 (1.80-4.87)
0.0004
<0.001
1.14 (0.63-1.99)
1.20 (0.70-2.05)
0.66
0.51
Preeclampsia 2.96 (1.35-7.03)
3.26 (1.51-7.08)
0.01
0.003
1.78 (0.75-4.02)
1.53 (0.72-3.25)
0.17
0.28
Chorioamnionitis 1.47 (0.74-2.97)
1.65 (0.86, 3.18)
0.28
0.13
0.77 (0.27-1.86)
0.64 (0.27-1.56)
0.58
0.33
CD (all) 1.58 (1.16-2.17)
1.50 (1.12-2.02)
0.004
0.007
1.28 (0.89-1.84)
1.42 (1.00-2.01)
0.18
0.05
CD labor arrest 2.37 (1.30-4.44)
2.65 (1.48-4.74)
0.006
0.001
1.24 (0.60-2.41)
1.33 (0.71-2.51)
0.55
0.37
SGA**
Treatment Group
No treatment
1.16 (0.54-2.45)
1.24 (0.59-2.58)
0.32 (0.13-0.73)
0.32 (0.14-0.73)
0.69
0.57
0.009
0.007
1.14 (0.43-2.69)
1.11 (0.46-2.68)
0.60 (0.17-1.66)
0.55 (0.19-1.62)
0.77
0.81
0.36
0.28
*Regression models included maternal race/ethnicity, maternal age, gestational age at enrollment, parity, pre-pregnancy BMI category (obese vs. 
non-obese), gestational age at delivery, gestational weight gain, and treatment group. Regression models for LGA and SGA excluded gestational 
age at delivery.
**
Final logistic regression model for SGA performed separately for treated and untreated groups because there was a significant interaction 
between treatment group and weight excess group.
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Table VI
Linear regression analysis results for association of excessive weight gain and of pre-pregnancy obesity with 
neonatal anthropomorphic characteristics.
Outcome Excessive weight gain P-value Pre-pregnancy Obesity P-value
Neonatal fat mass 54.5 (12.8) <0.001 37.4 (15.5) 0.02
Neonatal fat mass percent**
Treatment Group
No treatment
0.71 (−0.11-1.52)
1.14 (0.18-2.10)
0.09
0.02
−0.13 (−1.14-0.88)
1.90 (0.77-3.03)
0.80
0.001
Birth weight 155.6 (99.9-211.4) <0.001 35.6 (−31.5-102.7) 0.30
Data expressed as mean change (95% Confidence Interval)
*Regression models included maternal race/ethnicity, maternal age, gestational age at enrollment, parity, pre-pregnancy BMI category (obese vs. 
non-obese), gestational age at delivery, gestational weight gain, and treatment group.
**
Final linear regression model for neonatal fat mass percent performed separately for treated and untreated groups because there was a significant 
interaction between treatment group and pre-pregnancy BMI category.
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